Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with
advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20 …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …

Importance For more than a decade, sorafenib has been the only systemic treatment option
for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over …

Immune associated cells in the microenvironment have a significant impact on the
development and progression of hepatocellular carcinoma (HCC) and have received more …

abstract Despite significant research efforts, only a few treatment approaches have been
developed for hepatocellular carcinoma (HCC). In recent years, immune checkpoint …

Objective Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma
(HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70 …

Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis.
Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing …

Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular
carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib …

Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …